It was quite a busy and eventful day for the company.

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company ...

Bausch & Lomb (NYSE:BLCO) jumped 9% in premarket trading on a report that private equity firms TPG (TPG) and Blackstone (BX) ...

The approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...

TPG and Blackstone are teaming up to bid for Bausch + Lomb, with an expected valuation between $13 billion and $14 billion.

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

Fintel reports that on October 15, 2024, Evercore ISI Group upgraded their outlook for Bausch + Lomb (NYSE:BLCO) from In-Line ...

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

Mit aller Härte, die der Vater für nötig hält und die ihm selbst widerfahren ist, erzieht er den Sohn zum Hoferben. Doch der ...

Bausch + Lomb has teamed up with American sportscaster Erin Andrews to promote its dry eye disease treatment, launching the ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.